Research Article Details
| Article ID: | A25278 |
| PMID: | 22013810 |
| Source: | Zhongguo Zhong Xi Yi Jie He Za Zhi |
| Title: | [The key target of Chinese medicine treatment on alcoholic and nonalcoholic fatty liver disease: the gut]. |
| Abstract: | In recent years, the pathogenesis of "gut-liver axis" in alcoholic and nonalcoholic fatty liver disease has attracted more attention in this field. In this paper, the relationship among fatty liver, gut-permeability, gut-derived endotoxin, and gut microbiota was systematically clarified. Based on the researches of treatment and prevention of fatty liver and gut injury by Chinese medicine, the gut is believed as the curative target for fatty liver disease, which not only is the modern annotation for the Chinese medicine practice, but also might possibly become an important view angle and strategy for fatty liver disease treatment. |
| DOI: |
| Diseases ID | DO ID | Disease Name | Definition | Class |
|---|
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress | |
|---|---|---|---|---|---|---|---|
| D010 | Amoxicillin | Chemical drug | DB01060 | -- | -- | Under clinical trials | Details |
| D083 | CLA | Chemical drug | DB01211 | KCNH2; SLCO1B1; SLCO1B3 | -- | Under clinical trials | Details |
| D094 | Cysteamine | Chemical drug | DB00847 | GSS stimulant | Renal drug | Under clinical trials | Details |
| D095 | Cysteamine bitartrate | Chemical drug | DB00847 | -- | -- | Under clinical trials | Details |